ArticleNature communications2026

The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.

Anna Maria Di Giacomo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.